PHASE I, OPEN-LABEL, SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF AN H5 INFLUENZA PLASMID VACCINE (INO-3401) IN HEALTHY ADULTS PREVIOUSLY VACCINATED WITH VGX-3400X [EXTENSION OF 700054252]
Latest Information Update: 07 Nov 2021
At a glance
- Drugs INO 3401 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- Sponsors Inovio Pharmaceuticals
- 14 Jan 2013 New trial record